- Home
- OTLK vs ARL Comparison
OTLK vs ARL Comparison
Compare OTLK & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | ARL |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 261.7M |
| IPO Year | 2016 | 1999 |
Fundamental Metrics
Financial Performance| Metric | OTLK | ARL |
|---|---|---|
| Price | $1.02 | $15.36 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 13.4M | 16.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.91 | ★ 206.59 |
| EPS | N/A | ★ N/A |
| Revenue | $8,146,123.00 | ★ $50,014,000.00 |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $0.16 | $12.42 |
| 52 Week High | $3.39 | $24.44 |
Technical Indicators
Market Signals| Indicator | OTLK | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 39.75 |
| Support Level | $0.75 | $14.65 |
| Resistance Level | $1.83 | $15.83 |
| Average True Range (ATR) | 0.18 | 0.79 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 18.48 | 35.01 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.